Other studies addressed the issue of whether supplementation with ω3 PUFA to CRC patients undergoing chemotherapy could induce changes in inflammation markers, such as the ratio of C reactive protein (CRP) to albumin, considered a relevant clinical/inflammatory marker. Here, ALB is linked to colorectal carcinoma.